New Ray Medicine International Holding (HKSE:06108) Total Liabilities : HK$11.35 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Total Liabilities?

New Ray Medicine International Holding's Total Liabilities for the quarter that ended in Dec. 2023 was HK$11.35 Mil.

New Ray Medicine International Holding's quarterly Total Liabilities increased from Dec. 2022 (HK$14.19 Mil) to Jun. 2023 (HK$32.87 Mil) but then declined from Jun. 2023 (HK$32.87 Mil) to Dec. 2023 (HK$11.35 Mil).

New Ray Medicine International Holding's annual Total Liabilities declined from Dec. 2021 (HK$29.48 Mil) to Dec. 2022 (HK$14.19 Mil) and declined from Dec. 2022 (HK$14.19 Mil) to Dec. 2023 (HK$11.35 Mil).

New Ray Medicine International Holding Total Liabilities Historical Data

The historical data trend for New Ray Medicine International Holding's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Total Liabilities Chart

New Ray Medicine International Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

24.42

44.20

29.48

14.19

11.35

New Ray Medicine International Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															29.48	26.20	14.19	32.87	11.35

New Ray Medicine International Holding Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

New Ray Medicine International Holding's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.555	+	(0	+	5.795
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.35

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	491.603	-	480.253
	=	11.35

New Ray Medicine International Holding's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.555	+	(0	+	5.795
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.35

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	491.603	-	480.253
	=	11.35

New Ray Medicine International Holding Total Liabilities Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

New Ray Medicine International Holding (HKSE:06108) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN

Website

http://www.newraymedicine.com

New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.

Executives

Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping	2201 Interest of corporation controlled by you
Qian Shenglei	2101 Beneficial owner
Zhang Jiang	2201 Interest of corporation controlled by you
Yang Fang	2202 Interest of your spouse
Zhou Ling	2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines